$222.6M in CY2024 Part D spend460K claims · 126K beneficiaries · 329 plans surveyed
Questions a plan sponsor actually asks.
What is Suvorexant used for?
BELSOMRA ® (suvorexant) is indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.
Is there a generic for Suvorexant?
No. Suvorexant is brand-only with no generic equivalents currently in market.
How much does my plan pay for Suvorexant?
Across 329 Part D plans, Suvorexant averages $15.22/unit (NADAC). Lowest available: $15.22/unit. Highest in distribution: $15.23/unit.
Is Suvorexant on the FDA shortage list?
No. Suvorexant is not currently on the FDA Drug Shortage Database.
8 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.
Same class. Different math.
Sources · every number above traces back.
Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (4 approvals on file) · NADAC unit costs: CMS NADAC weekly file (4 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.